WO2020007227A1 - Procédé et kit de détection d'une rhino-sinusite chronique avec un sous-type de polypes nasaux et utilisation du gène alox15 en tant que biomarqueur - Google Patents

Procédé et kit de détection d'une rhino-sinusite chronique avec un sous-type de polypes nasaux et utilisation du gène alox15 en tant que biomarqueur Download PDF

Info

Publication number
WO2020007227A1
WO2020007227A1 PCT/CN2019/093281 CN2019093281W WO2020007227A1 WO 2020007227 A1 WO2020007227 A1 WO 2020007227A1 CN 2019093281 W CN2019093281 W CN 2019093281W WO 2020007227 A1 WO2020007227 A1 WO 2020007227A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
alox15
nasal
rna
detecting
Prior art date
Application number
PCT/CN2019/093281
Other languages
English (en)
Chinese (zh)
Inventor
张罗
王成硕
闫冰
Original Assignee
首都医科大学附属北京同仁医院
北京市耳鼻咽喉科研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810717413.XA external-priority patent/CN108949954A/zh
Priority claimed from CN201810720285.4A external-priority patent/CN108913764A/zh
Application filed by 首都医科大学附属北京同仁医院, 北京市耳鼻咽喉科研究所 filed Critical 首都医科大学附属北京同仁医院
Publication of WO2020007227A1 publication Critical patent/WO2020007227A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Definitions

  • the present disclosure belongs to the technical field of biomedicine, and particularly relates to a kit for detecting chronic sinusitis with nasal polyp subtype and the application of ALOX15 gene as a biomarker, and a method for detecting the expression level of ALOX15 gene in nasal exfoliated cells. .
  • CRSwNP Chronic rhinosinusitis with nasal polyps
  • CRSwNP is often accompanied by asthma and allergic rhinitis. It has been reported that 7% of asthma patients have CRSwNP and 26-48% of CRSwNP have asthma. The pathogenesis of CRSwNP is still uncertain.
  • CRSwNP can be divided into Eosinophilic (CRSwNP, ECRSwNP) and Nonosinophilic (CRSwNP, nonECRSwNP) according to the degree of eosinophil infiltration.
  • the clinical manifestations, medications and prognosis of the two are different.
  • the clinical symptoms of eosinophils are severe, mainly nasal congestion and decreased olfactory symptoms. Most patients have asthma, and the recurrence rate is higher.
  • the degree of eosinophil infiltration in nasal polyp tissue is most closely related to recurrence. When the percentage of cells in the tissue exceeds 27%, the risk of recurrence exceeds 90%.
  • the sensitivity of eosinophilic polyps to glucocorticoids is significantly higher than that of non-eosinophilic polyps.
  • the clinical symptoms of non-eosinophils are generally mild, and there is less chance of asthma, airway inflammation is lighter, and the postoperative recurrence rate is lower than that of eosinophils, and the response to macrolide therapy is good.
  • the western countries are mainly eosinophils, which mainly show TH2 inflammatory response, while the proportion of eosinophils and non-eosinophils in China is about half, and the non-eosinophils mainly show TH1 / TH17 is predominantly inflammatory.
  • the eosinophilic and non-eosinophilic types are significantly different in immunopathological types, clinical symptoms, drug response, and prognosis.
  • Different chronic sinusitis with nasal polyps have different inflammatory / pathological typing treatment strategies. Therefore, the identification of the pathological classification of chronic sinusitis with nasal polyps is particularly important.
  • the judgment of the two subtypes is mainly based on the staining of histopathological specimens after nasal mucosal biopsy, and the lack of non-invasive biological markers for differential diagnosis.
  • the patients were routinely treated with pathological specimens such as paraffin fixation, and then stained with hematoxylin and eosin, and then the tissue-infiltrated inflammatory cells were observed with a high-power microscope (mainly inflammatory cells include eosinophil , Neutrophils, lymphocytes, plasma cells) infiltration number for cell typing.
  • pathological specimens such as paraffin fixation
  • hematoxylin and eosin mainly inflammatory cells include eosinophil , Neutrophils, lymphocytes, plasma cells
  • the disadvantages of nasal mucosal biopsy are as follows: 1.
  • kits for detecting chronic sinusitis with nasal polyp subtype wherein the kit includes a specific primer for the ALOX15 gene.
  • the present disclosure also provides an application of ALOX15 gene as a biomarker in the preparation of a product for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides the use of the ALOX15 gene as a biomarker for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides the use of the kit according to the present disclosure for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides the use of a reagent for detecting ALOX15 for detecting chronic sinusitis with nasal polyp subtypes.
  • the present disclosure also provides a method for detecting the expression level of ALOX15 gene in nasal cavity exfoliated cells, including the following steps: extracting RNA from nasal cavity exfoliated cells, reverse transcription of total RNA into cDNA, and using quantitative polymerase chain reaction to convert ALOX15 in cDNA Genes and internal reference genes were amplified by real-time fluorescent quantitative PCR using specific primers of the ALOX15 gene and specific primers of the internal reference gene, and the expression of ALOX15 gene was calculated based on the detection results of the amplified products.
  • the present disclosure also provides an application of the above method for detecting the expression level of ALOX15 gene in nasal exfoliated cells in preparing a kit for detecting a chronic sinusitis subtype with nasal polyps.
  • the present disclosure also provides a method for detecting a chronic sinusitis subtype with nasal polyps, which comprises detecting the ALOX15 gene expression amount in nasal exfoliated cells by the method described in the present disclosure.
  • the present disclosure also provides a method for detecting a chronic sinusitis subtype with nasal polyps, comprising detecting and detecting the expression level of ALOX15 gene in nasal exfoliated cells, preferably using the kit of the present disclosure to detect Expression of ALOX15 gene.
  • FIG. 1 is a real-time fluorescent quantitative PCR amplification curve diagram of ALOX15 gene as part of an experimental example of the present disclosure
  • FIG. 2 is a real-time quantitative PCR amplification curve diagram of ALOX15 gene in another part of the experimental example of the present disclosure
  • FIG. 3 is a real-time quantitative PCR amplification curve diagram of ALOX15 gene in the experimental example of the present disclosure
  • FIG. 4 is a real-time fluorescent quantitative PCR amplification curve diagram of ALOX15 gene in another part of the experimental example of the present disclosure
  • FIG. 5 is a melting curve diagram of ALOX15 gene real-time quantitative PCR
  • FIG. 6 is a melting curve diagram of ALOX15 gene real-time quantitative PCR in another part of the experimental example of the present disclosure
  • FIG. 7 is a melting curve diagram of the ALOX15 gene real-time quantitative PCR in the experimental example of the present disclosure.
  • FIG. 8 is a melting curve diagram of the ALOX15 gene real-time quantitative PCR, which is part of the experimental example of the present disclosure.
  • FIG. 9 is an optional ROC curve for detecting chronic sinusitis with nasal polyp typing in Experimental Example 1 of the present disclosure.
  • FIG. 10 is a real-time fluorescent quantitative PCR amplification curve of ALOX15 gene in the second part of the experimental example of the present disclosure.
  • FIG. 11 is a real-time quantitative PCR amplification curve diagram of ALOX15 gene in another part of Experimental Example 2 of the present disclosure.
  • FIG. 12 is a real-time fluorescent quantitative PCR amplification curve diagram of ALOX15 gene in a second part of Experimental Example 2 of the present disclosure
  • FIG. 15 is a melting curve diagram of the ALOX15 gene real-time quantitative PCR in a second part of the experimental example of the present disclosure.
  • 16 is a real-time fluorescent quantitative PCR amplification curve of ALOX15 gene in Experimental Example 3 of the present disclosure
  • FIG. 17 is a melting curve diagram of real-time fluorescent quantitative PCR of ALOX15 gene in Experimental Example 3 of the present disclosure.
  • FIG. 19 is a melting curve diagram of ALOX15 gene real-time quantitative PCR in Experimental Example 4 of the present disclosure.
  • primer refers to an oligonucleotide that is capable of specifically annealing to an RNA or DNA region site adjacent to a target sequence, and as appropriate under conditions Primer for DNA synthesis. It is usually single-stranded, which can be naturally occurring or synthetic.
  • a “primer” or “oligonucleotide primer” typically comprises a sequence between about 5 to about 50 nucleotides, more preferably about 10 to about 30 nucleotides, or more preferably about 15 to 25 cores Glycylic acid.
  • the term "upstream primer” as used herein generally binds to a region closer to the 5 ' end of the nucleic acid molecule.
  • the term “downstream primer” as used herein generally binds to a region closer to the 3 'end of the nucleic acid molecule relative to a region on the nucleic acid to be amplified.
  • the term “internal reference gene” generally refers to a gene that is expressed relatively constant in various tissues and cells, such as GAPDH gene in nasal polyp tissue or cells exfoliated from nasal mucosa, and is mainly used as a reference when detecting gene expression levels.
  • polymerase chain reaction is the amplification of a nucleic acid consisting of: the initial denaturation step of separating the strands of a double-stranded nucleic acid sample, followed by repeating (i) allowing the amplification primers to be specific to the flanking position of the target sequence Annealing step of thermal annealing; (ii) an extending step of extending primers in the 5 'to 3' direction to form an amplicon polynucleotide complementary to the target sequence, and (iii) denaturation causing separation of the amplicon from the target sequence step.
  • the above steps can be performed at different temperatures, preferably using an automatic thermal cycler.
  • Real-time quantitative PCR also known as quantitative PCR, or QPCR for short, refers to adding a fluorescent group to a PCR reaction system, and using fluorescence signal accumulation to monitor the entire PCR process in real time. Method for quantitative analysis of unknown template by standard curve.
  • Ct cycle threshold
  • Ct value generally refers to the number of cycles that a fluorescent signal undergoes when a fluorescent signal reaches a set threshold.
  • the upstream primer of the ALOX15 gene is shown in SEQ ID NO: 2
  • the downstream primer of the ALOX15 gene is shown in SEQ ID NO: 3.
  • the kit further includes specific primers for internal reference genes.
  • the internal reference gene is GAPDH
  • the upstream primer of the internal reference gene is shown in SEQ ID NO: 4
  • the downstream primer of the ALOX15 gene is shown in SEQ ID NO: 5.
  • the kit further includes: a reagent for extracting RNA from nasal polyp tissue or detached cells from nasal mucosa; a reagent for reverse transcription of total RNA into cDNA; using quantitative polymerase chain reaction Reagent for performing real-time quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA.
  • the reagent for reverse transcription of total RNA into cDNA includes: a reverse transcription mixture and deRNase and deDNase water;
  • the reagent for reverse transcription of the total RNA into cDNA includes: 1 ⁇ L to 40 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 160 ⁇ L of deRNase and deDNase water. Further preferably, the reagent for reverse transcription of total RNA into cDNA includes: 2 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 8 ⁇ L of deRNase and DNAse dehydrating water.
  • a reagent for performing a real-time fluorescent quantitative PCR reaction of the ALOX15 gene and an internal reference gene in a cDNA using a quantitative polymerase chain reaction includes a PCR premix solution, double distilled water, machine fluorescence compensation, and a corrector. , The upstream primer of the ALOX15 gene, the downstream primer of the ALOX15 gene, the upstream primer of the internal reference gene, and the downstream primer of the internal reference gene.
  • a reagent for performing a real-time fluorescent quantitative PCR reaction of the ALOX15 gene and an internal reference gene in the cDNA by quantitative polymerase chain reaction includes: 1 ⁇ L to 25 ⁇ L of a PCR master mix, and 0 ⁇ L to 50 ⁇ L of a double-distillation Water, 0 ⁇ L to 2 ⁇ L of machine fluorescence compensation and correction agent, 0.01 to 100 ⁇ M of the ALOX15 gene upstream primer, 0.01 to 100 ⁇ M of the ALOX15 gene downstream primer, 0.01 to 100 ⁇ M of the internal reference gene upstream primer, 0.01 to 100 ⁇ M of the internal reference gene Downstream primers; Further preferably, the reagent for performing real-time quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction includes: 5 ⁇ L of PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water, according to the total volume Make up to 10 ⁇ L
  • the reagent for extracting RNA from nasal polyp tissue can be selected from the following two reagents.
  • the first type includes: RNA extraction solution, chloroform, isopropanol, 65% to 90% ethanol, RNase and DNAse-free water; among these, preferably, 0.1 mL to 20 mL of RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other substances containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate or ⁇ -mercaptoethanol, the Trizol or the RNAiso Blood or the RNAiso Plus Or 0.1 to 0.5 times the volume of the other substance containing phenol, guanidine isothiocyanate, 8-quinolinol, guanidine isothiocyanate, or ⁇ -mercaptoethanol, and 0.5 to 3 times the volume of the chloroform Isopropyl alcohol, 0.5 to 5 times the volume of isopropyl alcohol, 65% to 90% ethanol, and 0.01mL to 5mL of RNase and DNase water; further preferably
  • the reagent for extracting RNA from nasal polyp tissue includes: a cell lysate, a first buffer solution for removing impurities from the purification column to which RNA is adsorbed, and an impurity for removing impurities from the purification column to which RNA is adsorbed And saline second buffer solution and deRNase and DNase water;
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; wherein the reagent for extracting RNA from nasal polyp tissue also includes DNase
  • the reaction solution or the tool for extracting RNA from nasal polyp tissue also includes a genomic DNA adsorption column;
  • the DNase reaction solution includes a DNase buffer solution, a recombinant DNase, and a double-distilled water of deRNase.
  • the reagent for extracting RNA from nasal polyp tissue includes: 0.1 mL to 2 mL of a cell lysate for lysing cells and inhibiting RNA degradation, and 0.1 mL to 0.7 mL of a washing agent
  • a washing agent One buffer, 0.1 mL to 0.7 mL of second buffer for washing, 0.01 mL to 1 mL of RNase and DNase-free water, 0 to 10 ⁇ L of genomic DNA-recombinant DNase, and 0 to 10 ⁇ L of genomics DNA DNase buffer, 20 to 100 ⁇ L of RNase-free double-distilled water
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; or includes 0.1 mL to 2 mL for lysing cells and inhibiting RNA degradation Cell lysate, 0.1 mL to 0.7 mL of first buffer for washing, 0.1 mL to 0.7 mL of second buffer for washing, 0.01 mL to 1 m
  • the reagent for extracting RNA from nasal polyp tissue includes: 300 ⁇ L of a cell lysate for lysing cells and inhibiting RNA degradation, 500 ⁇ L of a first buffer for washing, and 600 ⁇ L of washing Use a second buffer, 0.02 mL of RNase and DNase-free water, 4 ⁇ L of genomic DNA-recombinant DNase, 5 ⁇ L of 10 ⁇ genomic DNA-removed DNase buffer, 41 ⁇ L of RNase-free double-distilled water
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; or includes 300 ⁇ L of a cell lysate for lysing cells and inhibiting RNA degradation, 500 ⁇ L of a first buffer for washing, and 600 ⁇ L of a second buffer for washing Solution, 0.02 mL of RNase and DNase water
  • the tools for extracting RNA from nasal polyp tissue include genomic DNA adsorption column and RNA purification column.
  • the nasal polyp tissue is nasal polyp tissue obtained from nasal pathological biopsy, or the nasal mucosa exfoliated cells are nasal polyp cells obtained by brushing or sticking to the surface of the nasal polyp.
  • the ⁇ Ct (Ct (ALOX15) -Ct (GAPDH)) analysis method is used to analyze the data result of the amplification product, and the cutoff value compared with the ⁇ Ct is 1.675.
  • the upstream primer of the ALOX15 gene is shown in SEQ ID NO: 2
  • the downstream primer of the ALOX15 gene is shown in SEQ ID NO: 3.
  • the internal reference gene is GAPDH
  • the upstream primer of the internal reference gene is shown in SEQ ID NO: 4
  • the downstream primer is shown in SEQ ID NO: 5.
  • the nasal cavity exfoliated cells are obtained by using a hair brush on the surface of the nasal polyp, and the hair brush after the nasal exfoliated cells are obtained is placed in a cell lysate and stored below 4 ° C.
  • the method for extracting RNA from exfoliated cells in the nasal cavity includes two methods, wherein the first method includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, add an equal volume of ethanol, mix well and add it to the RNA purification column. After centrifugation, remove the filtrate from the collection tube. The RNA purification column is placed in a collection tube;
  • Step 2 Add 300 ⁇ L to 700 ⁇ L of the first buffer to the RNA purification column obtained in step 1, and centrifuge to remove the first filtrate; continue to add 400 ⁇ L to 800 ⁇ L of the second buffer to the RNA purification column, After centrifugation, the second filtrate was removed, and an RNA purification column was eluted to obtain RNA.
  • the method for extracting RNA from exfoliated cells in the nasal cavity further includes the following steps: adding 10 to 100 ⁇ L of a DNase reaction solution to the RNA purification column after removing the second filtrate, and After the standing treatment, 300 ⁇ L to 700 ⁇ L of the second buffer solution was added, and after centrifugation, the third filtrate was removed. After the RNA purification column was eluted, the RNA purity was measured using a spectrophotometer to obtain RNA;
  • the method for preparing the DNase reaction solution includes the following steps: a DNase buffer solution, a recombinant DNase, and double-distilled water from which the RNase is removed are mixed to obtain a DNase reaction solution.
  • the method for preparing the DNase reaction solution includes the following steps: 5 ⁇ L of 10 ⁇ DNase buffer solution, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water are mixed to obtain a DNase reaction solution.
  • the method for extracting RNA from nasal cavity exfoliated cells further includes the following steps: in step 1 After the nasal cavity exfoliated cells are dissolved in the cell lysate, they are first added to a genomic DNA adsorption column to take a filtrate, and then an equal volume of ethanol is added to the filtrate.
  • the method for extracting RNA from exfoliated cells in the nasal cavity further includes the following steps: adding an RNA purification column to be eluted and adding distilled water to remove RNA hydrolase Or diethyl pyrocarbonate treated water, left at room temperature, centrifuged, and eluted the RNA purification column, and measured the purity of the RNA using a spectrophotometer to obtain RNA.
  • Step 1 uses a cell lysate that can rapidly break down nasal cells and inhibit nucleases released by nasal cells; genomic DNA adsorption columns are used to remove genomic DNA; RNA purification columns in step 2 are used to enrich RNA; The collection tube is used for collecting the solution after removing the genomic DNA, the first buffer solution for removing impurities in the purification column to which the RNA is adsorbed, and the second buffer solution for removing impurities and salts in the RNA solution.
  • the first method for extracting RNA from exfoliated nasal cells includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 300 ⁇ L of cell lysate, add an equal volume of 70% ethanol, and mix the solution evenly with a pipette; immediately add the mixed solution to the RNA purification column at 12000 rpm , Centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Take 5 ⁇ L of 10 ⁇ DNase buffer, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water to obtain a DNase reaction solution. Add 50 ⁇ L of DNase to the RNA purification column after removing the second filtrate. The reaction solution was left at room temperature for 15 minutes, 350 ⁇ L of the second buffer solution was added, 12000 rpm, and centrifuged for 30 seconds to remove the third filtrate;
  • Step 4 Place the RNA purification column with the third filtrate removed in step 3 in a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. After standing at room temperature for 5 minutes, 12000 rpm, centrifugation for 2 minutes, the RNA purification column was eluted, and the OD260 / OD280 ratio of the RNA solution was measured using a spectrophotometer to obtain an RNA of 1.7 to 2.1.
  • the method for extracting RNA from exfoliated cells in the nasal cavity includes the following steps:
  • Step 1 Take the genomic DNA adsorption column in a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, and add it to the genomic DNA adsorption column. Take the filtrate and add an equal volume of 70% ethanol, mixed well and added to the RNA purification column, 12000 rpm, centrifugation for 1min, the filtrate was removed, and the RNA purification column was placed in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. After standing at room temperature for 5 minutes, 12000 rpm, centrifugation for 2 minutes, the RNA purification column was eluted, and the OD260 / OD280 ratio of the RNA solution was measured using a spectrophotometer to obtain an RNA of 1.7 to 2.1.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 mL to 20 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for lysis 1. Add chloroform 0.1-0.5 times the volume of the RNA extraction solution after shaking, mix by shaking, leave it at room temperature, centrifuge the centrifuge tube, take the supernatant, and add 0.5-3 times the volume of chloroform.
  • Isopropyl alcohol stand still, centrifuge after mixing, discard the supernatant, retain the first precipitate, and add 0.5 to 5 times the volume of 65% to 90% ethanol of the isopropyl alcohol to the first precipitate, After washing, mix and centrifuge, discard the supernatant, and retain the second pellet; cover the centrifuge tube, centrifuge again, remove the supernatant, and continue to add 0.01 to 5 mL of RNase and DNAase to the centrifuge tube The second precipitate was dissolved in water, and the purity of the RNA was measured by a spectrophotometer to obtain RNA.
  • the RNA extraction solution is Trizol, RNAiso Blood, RNAiso Plus or other phenol, guanidinium isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, and ⁇ -mercapto group. Any one or several reagents in ethanol.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 to 20 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for dissolution and shaking After that, let stand at room temperature for 3 ⁇ 7min; add 40 ⁇ L ⁇ 5mL of chloroform, shake and mix well, let stand at room temperature for 3 ⁇ 7min, centrifuge at 3 °C ⁇ 5 °C, 10000 ⁇ 14000r / min for 10 ⁇ 20min; take the supernatant 40 ⁇ L ⁇ 8mL Add equal volume of isopropanol, mix and let stand for 8 ⁇ 12min, centrifuge at 3 °C ⁇ 5 °C, 10000 ⁇ 14000r / min for 10 ⁇ 20min, discard the supernatant and keep the first precipitate; Add 65% to 90% ethanol with the same volume as isopropanol, and centrifuge at 7000 to 14000 r / min for 10
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: After adding 1 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for dissolution and shaking, Let stand at room temperature for 5min; add 200 ⁇ L of chloroform, shake and mix, stand at room temperature for 5min, and centrifuge at 12,000r / min for 15min at 4 °C; take 200 ⁇ L of supernatant, add 200 ⁇ L of isopropanol, and let stand for 10min after mixing, and stand at 4 °C The supernatant was discarded by centrifugation at 12000 r / min for 15 min, and the first pellet was retained; 75% ethanol with an equal volume of isopropyl alcohol was added to the first pellet, and centrifuged at 7500 r / min for 15 min at 4 ° C, and the supernatant was discarded.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: taking 1 to 3 ⁇ L of the reverse transcription mixture, 0 to 10 ⁇ L of de-hydrolase distilled water and the extracted RNA at a temperature of 37 ° C. A reverse transcription reaction occurred under the conditions for 15 min, and then a reverse transcriptase inactivation reaction occurred at a temperature of 84 ° C to obtain a reverse transcription product cDNA.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: taking 2 ⁇ L of the reverse transcription mixture, 8 ⁇ L of the deRNA hydrolase distilled water, and a total amount not exceeding 500 ng or The volume does not exceed 8 ⁇ L of total RNA, and the de-RNA hydrolase distilled water is used to make up to 10 ⁇ L.
  • the reverse transcription reaction is performed under the following conditions: at 37 ° C, a reverse transcription reaction is performed for 15 minutes; at 85 Under the condition of °C, the reverse transcriptase inactivation reaction was performed for 5 seconds; the product was left at 4 °C.
  • the reaction system can be scaled up according to requirements.
  • a 10 ⁇ L reaction system can use a maximum of 500 ng of total RNA. Those skilled in the art can choose according to actual needs.
  • the real-time quantitative PCR amplification includes the following steps:
  • Step 1 Prepare a real-time quantitative PCR reaction solution: include 1 ⁇ L to 25 ⁇ L of PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water to make up the total volume of water to 10 ⁇ L, 0 ⁇ L to 2 ⁇ L of machine fluorescence compensation and correction agent, 0.01 to 100 ⁇ M Upstream primer of ALOX15 gene, downstream primer of ALOX15 gene of 0.01 to 100 ⁇ M, upstream primer of internal reference gene of 0.01 to 100 ⁇ M, downstream primer of internal reference gene of 0.01 to 100 ⁇ M, 0.01 ⁇ L to 5 ⁇ L of cDNA;
  • Step 2 Real-time quantitative PCR detection using standard two-step PCR amplification standard program or three-step PCR amplification standard program;
  • Step 3 Calculate the expression of ALOX15 gene.
  • a real-time quantitative PCR reaction solution is prepared: including 5 ⁇ L of a PCR premix, 2.8 ⁇ L of double distilled water to make up a total volume of water to 10 ⁇ L, 0.2 ⁇ L of a machine fluorescence compensation and correction agent, 0.5 ⁇ L of the ALOX15 upstream primer, 0.5 ⁇ L of the ALOX15 downstream primer, 0.5 ⁇ L of the internal reference gene upstream primer, 0.5 ⁇ L of the internal reference gene downstream primer, 1 ng / ⁇ L of the cDNA or 0.01 ⁇ L to 5 ⁇ L of all primers Mentioned RNA.
  • the reaction conditions of the standard two-step PCR amplification procedure include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR reaction: at 95 The reaction was carried out at a temperature of 15 ° C for 15 seconds, and at a temperature of 60 ° C for 60 seconds, followed by annealing and extension, and 40 cycles were performed.
  • the reaction conditions of the standard three-step PCR amplification procedure include the following steps: Stage 1: Pre-denaturation at 95 ° C for 2 minutes; Stage 2 PCR reaction: at 95 The reaction was performed at a temperature of 1 ° C for 1 minute, at 55 ° C for 1 minute, and at 72 ° C for 1 minute, and 40 cycles were thus performed. Finally, 72 ° C, annealed and extended for 7 minutes.
  • the reagent for detecting ALOX15 includes a specific primer for the ALOX15 gene, and preferably the upstream primer of the specific primer for the ALOX15 gene is as shown in SEQ ID NO: 2 and the ALOX15 gene The downstream primers are shown in SEQ ID NO: 3.
  • the reagent for detecting ALOX15 is selected from the group consisting of a primer, an antibody, an aptamer, a probe, or a combination thereof for ALOX15.
  • detection of ALOX15 gene level by fluorescent PCR method is used to detect chronic sinusitis with nasal polyp subtypes.
  • the amount of ALOX15 gene expression in nasal exfoliated cells is detected by fluorescent PCR.
  • chronic sinusitis with nasal polyp subtype is determined according to ⁇ Ct (Ct (ALOX15) -Ct (GAPDH)), Ct (ALOX15) is the Ct value of ALOX15 gene, and Ct (GAPDH) is Ct value of internal reference gene GAPDH.
  • the ⁇ Ct greater than or equal to 1.675 represents non-eosinophilic chronic sinusitis with nasal polyps, and the ⁇ Ct less than 1.675 represents eosinophilic chronic sinusitis with nasal polyps.
  • the chronic sinusitis with nasal polyp subtype is non-eosinophilic chronic sinusitis with nasal polyps or eosinophilic chronic sinusitis with nasal polyps.
  • the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtypes.
  • the proteomics and transcriptomics methods are used to select the ALOX15 gene as a biomarker and apply it to the kit to achieve A kit was used to detect chronic sinusitis with nasal polyp subtypes, so that the final kit obtained included specific primers for the ALOX15 gene.
  • the kit of the present disclosure can quickly identify nasal polyp subtypes, and is more accurate than traditional pathological detection methods.
  • the kit can simultaneously perform large-scale, rapid Testing, saving labor costs and medical treatment costs. And the systematic kit has high identification accuracy, which can fully reflect the histopathological characteristics.
  • the kit provided by the present disclosure can detect nasal polyp cells from the surface of the nasal polyp by brushing or sticking, so as to determine the chronic sinusitis of the patient with nasal polyp subtypes, avoiding causing the patient
  • the wound surface improves the safety of patient examination, and the operation is more convenient, saving labor costs and medical treatment costs.
  • the method for detecting the expression level of ALOX15 gene in nasal exfoliated cells provided by the present disclosure, using the effectively screened ALOX15 gene as a biomarker, and providing a method for detecting its gene expression level, thereby realizing the expression of ALOX15 gene in nasal exfoliated cells.
  • the calculation can effectively obtain the expression level of ALOX15 gene, and the provided method is simple, fast, sensitive, and reproducible, which is suitable for wide application.
  • ALOX15 gene in nasal exfoliated cells
  • the ALOX15 gene can encode a lipoxygenase protein
  • the encoded enzyme acts on various polyunsaturated fatty acid substrates to produce various biologically active lipids Medium, such as eicosanoid, heparin, lipoxin, etc.
  • the arachidonic acid was converted into 12-eicosatetraenoic acid / 12-HPETE and 15-eicosatetraenoic acid / 15-HPETE. It also converts linoleic acid into 13-hydroperoxyoctadecadienoic acid.
  • ALOX15 can also act on (12S) -hydrogen peroxytetraenoic acid / (12S) -HPETE to produce heparin A3.
  • the encoded enzyme and its reaction products can regulate inflammation and immune response.
  • Diseases related to ALOX15 include softening of white matter around the ventricle. It helps clear apoptotic cells during inflammation by oxidizing membrane-bound phosphatidylethanolamine in macrophages, and inhibits autoimmune responses associated with inflammatory monocytes clearing apoptotic cells.
  • the ALOX15 gene has not been disclosed in the prior art, and the use of the gene has not been found.
  • the method for the expression of ALOX15 gene in exfoliated nasal cells can be used to detect the expression of ALOX15 in exfoliated nasal cells, and it can be used to further provide a basis for the gene screening technology for detecting chronic sinusitis subtypes with nasal polyps, It provides a reliable basis for clinical guidance and drug treatment. The feasibility of the kit for detecting chronic sinusitis subtype with nasal polyps in clinical application is guaranteed.
  • nasal shedding method of detecting expression of genes in cells of the present disclosure provides ALOX15, using ⁇ Ct or 2 - ⁇ relative quantification method Ct method according to actual needs, the expression of selected relatively constant reference gene, carried out with the number of reference gene Standardization. Calculate the expression of the target gene by measuring the difference between the Ct value of the target gene and the internal reference gene. The method is simple and fast, the detection accuracy is high, the detection cost can be reduced, and the detection time can be saved. The result is easy to interpret and so on. Greatly improved the experimental efficiency.
  • chronic sinusitis with nasal polyp subtype is detected by detecting the level of ALOX15 protein in nasal lesion tissue of sinusitis with nasal polyps.
  • a nasal cavity tissue sample of chronic sinusitis with nasal polyps is obtained by, for example, nasal endoscopy, and the protein level of ALOX15 in the sample is determined by, for example, immunohistochemistry.
  • the protein level of ALOX15 in the sample is determined using an antibody against ALOX15.
  • an antibody against ALOX15 for detecting chronic sinusitis with nasal polyp subtypes is provided.
  • the embodiment of the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtype, the kit includes a specific primer of ALOX15 gene.
  • the present disclosure obtains a kit for detecting chronic sinusitis with nasal polyp subtypes by using the ALOX15 gene as a biomarker through proteomics and transcriptomics methods through a large number of creative experiments and screenings, which are not currently provided in the existing technology. Any reports accordingly.
  • the ALOX15 gene is a known gene, the gene ID is 246, the DNA sequence is shown in SEQ ID NO: 1, and the gene NM number is 001140.4.
  • the upstream primer of the ALOX15 gene is shown in SEQ ID NO: 2
  • the downstream primer of the ALOX15 gene is shown in SEQ ID NO: 3.
  • the kit of the present disclosure has the highest accuracy and more effective in identifying nasal polyp subtypes, which makes the kit suitable for large-scale and rapid detection.
  • the kit further includes a reference gene. More preferably, the internal reference gene is GAPDH, the upstream primer of the internal reference gene is shown in SEQ ID NO: 4, and the downstream primer of the ALOX15 gene is shown in SEQ ID NO: 5.
  • the upstream and downstream primers of the internal reference gene determined by the kit of the present disclosure can effectively obtain the appropriate ⁇ CT value by displaying the expression of the ALOX15 gene compared to GAPDH when identifying the nasal polyp subtypes of the kit of the present disclosure. Identification of nasal polyp subtypes. And has a higher accuracy.
  • the kit further comprises: a reagent for extracting RNA from nasal polyp tissue or detached cells from nasal mucosa; a reagent for reverse transcription of total RNA into cDNA; and a quantitative polymerase chain reaction for converting cDNA Reagents for the ALOX15 gene and internal reference genes for real-time quantitative PCR reactions.
  • the reagent for reverse transcription of total RNA into cDNA includes: a reverse transcription mixed solution and de-RNase and de-DNase water; using quantitative polymerase chain reaction to perform real-time ALOX15 gene and internal reference gene in cDNA
  • the reagents for the quantitative PCR reaction include: PCR premix, double-distilled water, machine fluorescence compensation and correction agent, upstream primer of ALOX15 gene, downstream primer of ALOX15 gene, upstream primer of internal reference gene, and downstream primer of internal reference gene.
  • RNA extraction solution chloroform, isopropanol, 65% to 90% ethanol, RNase and DNA. Enzyme water
  • the reagent for extracting RNA from nasal polyp tissue includes: a cell lysate, a first buffer solution for removing impurities from the purification column to which RNA is adsorbed, and an impurity for removing impurities from the purification column to which RNA is adsorbed And saline second buffer solution and deRNase and DNase water;
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; wherein the reagent for extracting RNA from nasal polyp tissue also includes DNase
  • the reaction solution or the tool for extracting RNA from nasal polyp tissue also includes a genomic DNA adsorption column;
  • the DNase reaction solution includes a DNase buffer solution, a recombinant DNase, and a double-distilled water of deRNase.
  • the reagent for reverse transcription of total RNA into cDNA includes: 1 ⁇ L to 40 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 160 ⁇ L of deRNase and DNAse dehydrating water. Further preferably, the reagent for reverse transcription of the total RNA into cDNA includes: 2 ⁇ L of a reverse transcription mixed solution, and 0 ⁇ L to 8 ⁇ L of deRNase and DNAase water (completed to 8 ⁇ L with water according to the amount of RNA).
  • the reverse transcription step can be realized, and for those skilled in the art, it can be selected according to actual needs.
  • the reagents for performing real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction include: 1 ⁇ L to 25 ⁇ L PCR premix, 0 ⁇ L to 50 ⁇ L double-distilled water, and 0 ⁇ L to 2 ⁇ L machine Fluorescence compensation and correction agent, 0.01 to 100 ⁇ M upstream primer of ALOX15 gene, 0.01 to 100 ⁇ M downstream primer of ALOX15 gene, 0.01 to 100 ⁇ M internal reference gene upstream primer, 0.01 to 100 ⁇ M internal reference gene downstream primer; more preferably,
  • the reagents for real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction include: 5 ⁇ L of PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water (make up to 10 ⁇ L with water based on the total volume), 0.2 ⁇ L of machine fluorescence compensation and correction agent, 1 ⁇ M of the A
  • the following two reagents can be selected.
  • the first includes: 0.1 mL to 20 mL of RNA extraction solution Trizol or RNAiso, Blood or RNAiso Plus or other phenol, isothiocyanate Guanidine acid, 8-hydroxyquinoline, guanidine isothiocyanate, or ⁇ -mercaptoethanol, the Trizol or the RNAisoBlood or the RNAisoPlus or the other substances containing phenol, guanidine isothiocyanate, 8- Hydroxyquinoline, guanidine isothiocyanate, or ⁇ -mercaptoethanol are 0.1 to 0.5 times the volume of chloroform, 0.5 to 3 times the volume of isopropyl alcohol, and 0.5 to 5 times the volume of isopropyl alcohol. 65% to 90% ethanol, and 0.01mL to 5mL of RNase and DNase water;
  • Another type includes: 0.1 mL to 2 mL of a cell lysate for lysing cells and inhibiting RNA degradation, 0.1 mL to 0.7 mL of a first buffer for washing, 0.1 mL to 0.7 mL of a second buffer for washing, 0.01mL to 1mL of RNase and DNase-free water, 0 to 10 ⁇ L of genomic DNA-recombinant DNase, 0 to 10 ⁇ L of genomic DNA-removed DNase buffer, 20 to 100 ⁇ L of RNase-free double distillation Water
  • the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; or includes 0.1 mL to 2 mL of a cell lysate for lysing cells and inhibiting RNA degradation, and 0.1 mL to 0.7 mL of a first buffer for washing 0.1 to 0.7 mL of a second buffer solution for washing, 0.01 to 1 mL of RNase and DNase water, and the tools for extract
  • the following two reagents can be selected, the first includes: 1 mL of RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other phenol, guanidine isothiocyanate , 8-hydroxyquinoline, guanidine isothiocyanate or ⁇ -mercaptoethanol, 200 ⁇ L of chloroform, 200 ⁇ L of isopropanol, 200 ⁇ L of 65% to 90% ethanol by volume, and 0.02 mL of deRNase and DNAse-free water; the names of the RNA extraction solutions are Trizol, RNAiso Blood, and RNAiso Plus are all trade names.
  • Another type includes: 300 ⁇ L of cell lysate for lysing cells and inhibiting RNA degradation, 500 ⁇ L of first buffer for washing, 600 ⁇ L of second buffer for washing, 0.02 mL of RNase and DNase Water, 4 ⁇ L of genomic DNA-removed recombinant DNase, 5 ⁇ L of 10 ⁇ genomic DNA-removed DNase buffer, 41 ⁇ L of de-RNase double-distilled water, the tool for extracting RNA from nasal polyp tissue includes an RNA purification column; Alternatively, it includes 300 ⁇ L of a cell lysate for lysing cells and inhibits RNA degradation, 500 ⁇ L of a first buffer for washing, 600 ⁇ L of a second buffer for washing, 0.02 mL of RNase and DNase water, Tools for extracting RNA from nasal polyp tissue include genomic DNA adsorption columns and RNA purification columns. For the above-mentioned limited numerical ranges, the steps of extracting RNA from nasal polyp tissue can be realized
  • the cell lysate described above is used to rapidly disrupt cells and inhibit the release of nucleases from cells.
  • the first buffer is used to remove impurities from the purification column to which RNA is adsorbed, and the second buffer is used to remove the RNA that is adsorbed.
  • the impurities and salts of the purification column, de-RNase and DNase-free water are used to dissolve the RNA.
  • reagents for extracting RNA from nasal polyp tissue reagents for reverse transcription of total RNA into cDNA
  • reagents for quantitative real-time PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction reagents for quantitative real-time PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction .
  • the nasal polyp tissue is nasal polyp tissue obtained from nasal pathological biopsy, or the nasal mucosa exfoliated cells are nasal polyp cells obtained by brushing or sticking to the surface of the nasal polyp.
  • the brushing or sticking method is used to avoid wounds to the patient, improve the safety of patient examination, and make the operation more convenient, saving labor costs and medical treatment costs.
  • the ⁇ Ct (Ct (ALOX15) -Ct (GAPDH)) analysis method is used to analyze the data result of the amplification product, and the limit value for comparison with the ⁇ Ct is 1.675.
  • the defined value can enable the kit provided by the present disclosure to achieve an accuracy rate of more than 75% when detecting chronic sinusitis with nasal polyp subtypes.
  • An embodiment of the present disclosure also provides an application of the ALOX15 gene as a biomarker in preparing a product for detecting chronic sinusitis with nasal polyp subtypes.
  • the product may be a detection reagent, a chip or a kit.
  • the above embodiments only describe the specific technical content of the kit, for those skilled in the art, based on the disclosure of the technical solution of the present application, combined with common general knowledge, the specific technical content of the detection reagents and chip products can be directly obtained. .
  • An embodiment of the present disclosure provides a method for detecting the expression level of ALOX15 gene in nasal exfoliated cells, including the following steps: extracting RNA from nasal exfoliated cells, reverse-transcribe total RNA into cDNA, and use quantitative polymerase chain reaction to convert the The ALOX15 gene and internal reference gene were amplified by real-time fluorescent quantitative PCR using specific primers of the ALOX15 gene and specific primers of the internal reference gene, respectively. The expression of ALOX15 gene was calculated based on the detection results of the amplified products.
  • the present disclosure uses proteomics and transcriptomics methods to screen a large number of creative experiments to obtain a subtype of chronic sinusitis with nasal polyps by calculating the expression of ALOX15 gene, and provides a simple and reliable method for calculating the expression of ALOX15 gene. , High accuracy. No corresponding reports have been provided in the existing technology.
  • the ALOX15 gene is a known gene, the gene ID is 246, the DNA sequence is shown in SEQ ID NO: 1, and the gene NM number is 001140.4.
  • the upstream primer of the ALOX15 gene is shown in SEQ ID NO: 2
  • the downstream primer of the ALOX15 gene is shown in SEQ ID NO: 3.
  • the design of the upstream and downstream primers of the ALOX15 gene has higher sensitivity. When detecting the expression of the ALOX15 gene, the results are more accurate and repeatable.
  • the internal reference gene is GAPDH
  • the upstream primer of the internal reference gene is shown in SEQ ID NO: 4
  • the downstream primer is shown in SEQ ID NO: 5.
  • the nasal cavity exfoliated cells are obtained by using a hair brush on the surface of the nasal polyps, and the hair brush after obtaining the nasal cavity exfoliated cells is placed in a cell lysate and stored below 4 ° C. Based on this method, the method of the present disclosure avoids wounds to patients, improves the safety of patient examination, and is more convenient to operate, saving labor costs and medical treatment costs.
  • the method for extracting RNA from exfoliated nasal cells includes two methods, wherein the first method includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, add an equal volume of ethanol, mix well and add it to the RNA purification column. After centrifugation, remove the filtrate from the collection tube. The RNA purification column is placed in a collection tube;
  • Step 2 Add 300 ⁇ L to 700 ⁇ L of the first buffer to the RNA purification column obtained in step 1, and centrifuge to remove the first filtrate; continue to add 400 ⁇ L to 800 ⁇ L of the second buffer to the RNA purification column, After centrifugation, the second filtrate was removed, and an RNA purification column was eluted to obtain RNA.
  • the method for extracting RNA from exfoliated cells in the nasal cavity further comprises the following steps: adding 10 to 100 ⁇ L of a DNase reaction solution to the RNA purification column after removing the second filtrate, and after standing treatment, adding 300 ⁇ L ⁇ 700 ⁇ L of the second buffer solution, after centrifugation, remove the third filtrate, take the RNA purification column and elute the RNA purity using a spectrophotometer to obtain RNA;
  • the method for preparing the DNase reaction solution includes the following steps: a DNase buffer solution, a recombinant DNase, and double-distilled water from which the RNase is removed are mixed to obtain a DNase reaction solution.
  • the method for preparing the DNase reaction solution includes the following steps: 5 ⁇ L of 10 ⁇ DNase buffer solution, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water are mixed to obtain a DNase reaction solution.
  • the method for extracting RNA from nasal cavity exfoliated cells when the genome content is low or the starting amount of material is low when performing RNA extraction further includes the following steps: in step 1, the nasal exfoliated cells are lysed After the cell lysate is added to a genomic DNA adsorption column to take a filtrate, an equal volume of ethanol is added to the filtrate.
  • the method for extracting RNA from nasal cavity exfoliated cells further includes the following steps: adding an RNA purification column to be eluted and adding distilled water to remove RNA hydrolase or diethyl pyrocarbonate treatment After the water was left at room temperature, the RNA purification column was eluted by centrifugation, and the RNA purity was measured by a spectrophotometer to obtain RNA.
  • Step 1 uses a cell lysate that can rapidly break down nasal cells and inhibit nucleases released by nasal cells; genomic DNA adsorption columns are used to remove genomic DNA; RNA purification columns in step 2 are used to enrich RNA; The collection tube is used for collecting the solution after removing the genomic DNA, the first buffer solution for removing impurities in the purification column to which the RNA is adsorbed, and the second buffer solution for removing impurities and salts in the RNA solution.
  • the first method for extracting RNA from exfoliated nasal cells includes the following steps:
  • Step 1 Dissolve the nasal cavity exfoliated cells in 300 ⁇ L of cell lysate, add an equal volume of 70% ethanol, and mix the solution evenly with a pipette; immediately add the mixed solution to the RNA purification column at 12000 rpm , Centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Take 5 ⁇ L of 10 ⁇ DNase buffer, 4 ⁇ L of recombinant DNase, and 41 ⁇ L of RNase-free double-distilled water to obtain a DNase reaction solution. Add 50 ⁇ L of DNase to the RNA purification column after removing the second filtrate. The reaction solution was left at room temperature for 15 minutes, 350 ⁇ L of the second buffer solution was added, 12000 rpm, and centrifuged for 30 seconds to remove the third filtrate;
  • Step 4 Place the RNA purification column with the third filtrate removed in step 3 in a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. After standing at room temperature for 5 minutes, 12000 rpm, centrifugation for 2 minutes, the RNA purification column was eluted, and the OD260 / OD280 ratio of the RNA solution was measured using a spectrophotometer to obtain an RNA of 1.7 to 2.1.
  • the method for extracting RNA from exfoliated nasal cells includes the following steps:
  • Step 1 Take the genomic DNA adsorption column in a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 100-2000 ⁇ L of cell lysate, and add it to the genomic DNA adsorption column. Take the filtrate and add an equal volume of 70% ethanol, mixed well and added to the RNA purification column, 12000 rpm, centrifugation for 1min, the filtrate was removed, and the RNA purification column was placed in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. After standing at room temperature for 5 minutes, 12000 rpm, centrifugation for 2 minutes, the RNA purification column was eluted, and the OD260 / OD280 ratio of the RNA solution was measured using a spectrophotometer to obtain an RNA of 1.7 to 2.1.
  • step 1 uses a cell lysate to rapidly break down nasal cells and inhibit nuclease released by nasal cells;
  • step 1 uses a genomic DNA adsorption column to remove genomic DNA; and an RNA purification column in step 2 is used for enrichment RNA;
  • the collection tube is used to collect the solution after removing the genomic DNA, the first buffer is used to remove impurities from the purification column to which the RNA is adsorbed, and the second buffer is used to remove impurities and salts from the RNA solution.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 mL to 20 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells, lysing, shaking and adding 0.1 to 0.5 times the volume of the chloroform of the RNA extraction solution, shake and mix, and stand at room temperature, centrifuge the centrifuge tube, take the supernatant, and add 0.5 to 3 times the volume of chloroform in isopropyl alcohol.
  • RNA purity is measured by a spectrophotometer to obtain RNA.
  • the RNA extraction solution is any one or more of Trizol, RNAisoBlood, RNAisoPlus or other phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate and ⁇ -mercaptoethanol.
  • Trizol Trizol
  • RNAisoBlood RNAisoPlus or other phenol
  • guanidine isothiocyanate 8-hydroxyquinoline
  • guanidine isothiocyanate and ⁇ -mercaptoethanol.
  • reagents are examples of Trizol, RNAisoBlood, RNAisoPlus or other phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate and ⁇ -mercaptoethanol.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 0.1 to 20 mL of RNA extraction solution to a centrifuge tube containing nasal exfoliated cells for dissolution, shaking, and room temperature Let stand for 3 ⁇ 7min; add 40 ⁇ L ⁇ 5mL of chloroform, shake and mix well, let stand at room temperature for 3 ⁇ 7min, centrifuge at 3 °C ⁇ 5 °C, 10000 ⁇ 14000r / min for 10 ⁇ 20min; take the supernatant 40 ⁇ L ⁇ 8mL, add etc.
  • the volume of isopropanol was mixed and left to stand for 8-12 minutes, centrifuged at 3 ° C to 5 ° C, 10,000 to 14000 r / min for 10 to 20 minutes, the supernatant was discarded, and the first precipitate was retained;
  • Propanol equal volume of 65% to 90% ethanol was centrifuged at 3 ° C to 5 ° C, 7000 to 14000r / min for 10 to 20min, the supernatant was discarded, and the second pellet was retained;
  • the centrifuge tube was tightly closed at 3 ° C ⁇ 5 ° C, centrifuge at 7000 ⁇ 14000r / min for 1 ⁇ 3min, remove the supernatant, and let stand for 10 ⁇ 20min, then continue to add 0.01 ⁇ 5mL of deRNase and deDNase water to the centrifuge tube to dissolve the second Precipitate and measure RNA purity using a spectrophotometer to obtain RNA.
  • the second method for extracting RNA from nasal cavity exfoliated cells includes the following steps: adding 1 mL of RNA extraction solution to a centrifuge tube containing nasal cavity exfoliated cells for dissolution, shaking, and standing at room temperature for 5 min; adding 200 ⁇ L of chloroform, Mix by shaking, let stand at room temperature for 5 minutes, and centrifuge at 12,000 r / min for 15 min at 4 ° C. Take the supernatant 200 ⁇ L, add 200 ⁇ L isopropanol, mix and let stand for 10 min, and centrifuge at 4 ° C for 15 min at 12000 r / min to discard the supernatant.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: 1 to 3 ⁇ L of the reverse transcription mixed solution, 0 to 10 ⁇ L of de-hydrolase-distilled water and the extracted RNA undergo a reverse transcription reaction at a temperature of 37 ° C. After 15 min, a reverse transcriptase inactivation reaction occurred at a temperature of 84 ° C to obtain a reverse transcription product cDNA.
  • the method for reverse transcription of total RNA into cDNA includes the following steps: taking 2 ⁇ L of the reverse transcription mixture, 8 ⁇ L of the deRNA hydrolase distilled water, and a total amount not exceeding 500 ng or a volume not exceeding
  • the de-hydrolase enzyme distilled water is used to make up to 10 ⁇ L
  • the reverse transcription reaction is performed after gentle mixing, the conditions are as follows: at 37 ° C, the reverse transcription reaction is performed for 15 minutes; at 85 ° C, Under the conditions, an inactivation reaction of reverse transcriptase was performed for 5 seconds; the product was left at 4 ° C.
  • the real-time quantitative PCR amplification includes the following steps:
  • Step 1 Prepare a real-time quantitative PCR reaction solution: include 1 ⁇ L to 25 ⁇ L of PCR premix, 0 ⁇ L to 10 ⁇ L of double distilled water to make up the total volume of water to 10 ⁇ L, 0 ⁇ L to 2 ⁇ L of machine fluorescence compensation and correction agent, 0.01 to 100 ⁇ M Upstream primer of ALOX15 gene, downstream primer of ALOX15 gene of 0.01 to 100 ⁇ M, upstream primer of internal reference gene of 0.01 to 100 ⁇ M, downstream primer of internal reference gene of 0.01 to 100 ⁇ M, 0.01 ⁇ L to 5 ⁇ L of cDNA;
  • Step 2 Real-time quantitative PCR detection using standard two-step PCR amplification standard program or three-step PCR amplification standard program;
  • Step 3 Calculate the expression of ALOX15 gene.
  • a real-time quantitative PCR reaction solution was prepared: including 5 ⁇ L of a PCR premix, 2.8 ⁇ L of double distilled water to make up a total volume of water to 10 ⁇ L, 0.2 ⁇ L of a machine fluorescence compensation and correction agent, and 0.5 ⁇ L of the upstream ALOX15 gene.
  • the reaction conditions of the standard two-step PCR amplification procedure include the following steps: first stage: pre-denaturing at 95 ° C for 30 seconds; second stage PCR reaction: at 95 ° C Under the conditions, the reaction is performed for 15 seconds, and the reaction is performed at 60 ° C for 60 seconds, and the annealing is extended, so that 40 cycles are performed;
  • the reaction conditions of the standard three-step PCR amplification procedure include the following steps: first stage: pre-denaturation at 95 ° C for 2 minutes; second stage PCR reaction: at 95 ° C, reaction for 1 minute, at The reaction is performed at 55 ° C for 1 minute, and at 72 ° C for 1 minute, so that 40 cycles are performed; finally, 72 ° C, 7 minutes of annealing and extension;
  • Relative quantification method using ⁇ CT method or 2- ⁇ Ct method selecting internal reference genes with relatively constant expression, normalizing with the number of internal reference genes, and calculating the target gene expression by measuring the difference between the Ct value of the target gene and the internal reference gene. It is simple and fast, and the detection accuracy is high, which can reduce the detection cost and save the detection time. The result is easy to interpret and so on. Greatly improved the experimental efficiency.
  • the expression of ALOX15 and the reference gene are different.
  • the reference gene is a gene that is more stable in vivo and usually does not change with diseases. Therefore, the comparison with the reference gene can reflect the relative abundance of the target gene and the reference gene. , You can use ⁇ CT method. For different subjects, the expression of ALOX15 and the reference gene can be different using the 2- ⁇ Ct method.
  • kits for detecting chronic sinusitis with nasal polyp subtypes provided by the embodiments of the present disclosure and the application of ALOX15 gene as a biomarker, and a method for detecting nasal cavity shedding provided by the embodiments of the present invention
  • ALOX15 gene expression in cells will be described below with reference to specific examples.
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents:
  • RNA extraction solution Trizol or RNAiso Blood or RNAisoPlus or other products containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, ⁇ -mercaptoethanol, etc.
  • Substances that can rapidly disrupt cells and inhibit nucleases released by the cells 2mL of chloroform; 20mL of isopropanol; 40mL of 65-90% ethanol; 5mL of RNase and DNAse-free water;
  • Reagent for reverse transcription of extracted RNA into cDNA 40 ⁇ L of reverse transcription mixture (containing reverse transcription enzymes, RNase inhibitors, random 6-nucleotide primers, polythymine, T repeat oligonucleotides , Deoxyribonucleotide triphosphate mixture, buffer solution, etc.), 160 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction 25 ⁇ L of premixed solution (containing enzymes and buffers required for PCR), 0 to 50 ⁇ L of double distilled water (based on total Make up volume to 50 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 100 ⁇ M upstream primer of ALOX15 gene, 100 ⁇ M downstream primer of ALOX15 gene, 100 ⁇ M upstream primer of internal reference gene, 100 ⁇ M
  • the downstream primer of the internal reference gene 10 ⁇ g positive control, 10 ⁇ g negative control, the positive control is a plasmid containing ALOX15, and the negative control is an empty plasmid (plasmid vector).
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents:
  • RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other substances containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, ⁇ -mercaptoethanol, etc.
  • Substances that can rapidly disrupt cells and inhibit the release of nucleases from cells 0.2mL of chloroform; 0.2mL of isopropanol; 0.2mL of 65-90% ethanol; 0.05mL of RNase and DNAse-free water;
  • Reagent for reverse transcription of extracted RNA into cDNA 2 ⁇ L of reverse transcription mixture (containing the enzyme required for reverse transcription, RNase inhibitor, random 6 nucleotide primers, polythymine, T repeat oligonucleotide , Deoxyribonucleotide triphosphate mixture, buffer solution, etc.), 7 ⁇ L of RNase and DNAse-free water; of which RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction 5 ⁇ L of premix (containing enzymes and buffers required for PCR), 0-10 ⁇ L of double-distilled water (based on total Make up volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 50 ⁇ M upstream primer of ALOX15 gene, 50 ⁇ M downstream primer of ALOX15 gene, 50 ⁇ M upstream primer of internal reference gene, 50 ⁇ M
  • the downstream primer of the internal reference gene 5 ⁇ g positive control, 5 ⁇ g negative control, the positive control is a plasmid containing ALOX15, and the negative control is an empty plasmid (plasmid vector).
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents:
  • RNA extraction solution Trizol or RNAiso Blood or RNAiso Plus or other containing phenol, guanidine isothiocyanate, 8-hydroxyquinoline, guanidine isothiocyanate, ⁇ -mercaptoethanol And other substances that can rapidly break down cells and inhibit the nuclease released by the cells; 0.05mL of chloroform; 0.015mL of isopropanol; 0.0075mL of 65-90% ethanol; 0.01mL of RNase and DNase-free water ;
  • Reagent for reverse transcription of total RNA into cDNA 1 ⁇ L of reverse transcription mixture (containing enzymes required for reverse transcription, RNase inhibitors, random 6 nucleotide primers, polythymine, T repeat oligonucleotides, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0-10 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Quantitative polymerase chain reaction reagent for real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA 1 ⁇ L of premixed solution (containing enzymes and buffers required for PCR), 0 to 10 ⁇ L of double-distilled water (based on total Make up volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 1 ⁇ M upstream primer of ALOX15 gene, 1 ⁇ M downstream primer of ALOX15 gene, 1 ⁇ M upstream primer of internal reference gene, 1 ⁇ M
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents and tools:
  • Reagents for RNA extraction from nasal polyp tissue 100 ⁇ L of cell lysate (RL buffer with 50 x dithiothreitol (DTT)), genomic DNA adsorption column for removing genomic DNA, and for collecting and removing genomic DNA
  • RL buffer with 50 x dithiothreitol (DTT) genomic DNA adsorption column for removing genomic DNA
  • genomic DNA adsorption column for removing genomic DNA
  • genomic DNA adsorption column for removing genomic DNA
  • genomic DNA adsorption column for removing genomic DNA
  • genomic DNA for collecting and removing genomic DNA
  • a collection tube for the solution an RNA purification column for enriching RNA, 0.1 mL of a first buffer for removing impurities from the purification column to which the RNA is adsorbed, and 0.1 mL of a second buffer for removing impurities and salts from the RNA solution Solution, centrifuge tube for collecting RNA, 0.01 mL of RNase and DNase water for dissolving
  • Reagent for reverse transcription of total RNA into cDNA 1 ⁇ L of reverse transcription mixture (containing enzymes required for reverse transcription, RNase inhibitors, random 6 nucleotide primers, polythymine, T repeat oligonucleotides, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0-10 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction 25 ⁇ L premix (containing enzymes and buffers required for PCR), 0-10 ⁇ L double-distilled water (based on total Make up volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 0.01 ⁇ M upstream primer of ALOX15 gene, 0.01 ⁇ M downstream primer of ALOX15 gene, 0.01 ⁇ M upstream of reference gene Primer, 0.01 ⁇ M of the internal reference gene downstream primer, 1 ⁇ g positive control, 1 ⁇ g negative control, the positive control is a plasmid containing ALOX15, and the negative control is an empty plasmid (plasmid vector).
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents and tools:
  • Reagent for RNA extraction from nasal polyp tissue 0.3 mL of cell lysate (RL buffer with 50 x dithiothreitol (DTT)), RNA purification column for enriching RNA, 0.5 mL for removing adsorbed The first buffer of impurities in the RNA purification column, 0.6 mL of the second buffer for removing impurities and salts from the RNA solution, 4 ⁇ L of genomic DNA-removing recombinant DNase, 5 ⁇ L of genomic DNA-removing DNase buffer , 41 ⁇ L double-distilled water for RNase, centrifuge tube for collecting RNA, 0.05 mL of RNase and DNase water for dissolving RNA;
  • Reagent for reverse transcription of total RNA into cDNA 2 ⁇ L of reverse transcription mixture (containing the enzyme required for reverse transcription, RNase inhibitor, random 6 nucleotide primers, polythymine, T repeat oligonucleotide, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0-10 ⁇ L of RNase and DNAse-free water; RNase and DNAse-free water are used to complete the system, solubilize and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction 5 ⁇ L of premix (containing enzymes and buffers required for PCR), 0-10 ⁇ L of double-distilled water (based on total Make up volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 10 ⁇ mol / L upstream primer of ALOX15 gene, 10 ⁇ mol / L downstream primer of ALOX15 gene, 10 ⁇ mol / L internal reference
  • a kit for detecting chronic sinusitis with nasal polyp subtypes comprising the following reagents and tools:
  • Reagents for RNA extraction from nasal polyps 2 mL of cell lysate (RL buffer with 50 x dithiothreitol (DTT)), a genomic DNA adsorption column for removing genomic DNA, and after collecting and removing genomic DNA
  • RL buffer with 50 x dithiothreitol (DTT) 2 mL of cell lysate
  • DTT dithiothreitol
  • a collection tube for the solution an RNA purification column for enriching RNA, 0.7 mL of a first buffer for removing impurities from the purification column to which the RNA is adsorbed, and 0.7 mL of a second buffer for removing impurities and salts from the RNA solution Liquid, centrifuge tube for collecting RNA, 1 mL of RNase and DNase water for dissolving RNA;
  • Reagent for reverse transcription of total RNA into cDNA 2 ⁇ L of reverse transcription mixture (containing the enzyme required for reverse transcription, RNase inhibitor, random 6 nucleotide primers, polythymine, T repeat oligonucleotide, Deoxyribonucleotide triphosphate mixtures, buffers, etc.), 0 ⁇ 8 ⁇ L of RNase and DNase water (make up to 8 ⁇ L with water according to the amount of RNA); RNase and DNase-free water is used for replenishment. Uniform system, dissolve and dilute RNA;
  • Reagent for real-time fluorescent quantitative PCR reaction of ALOX15 gene and internal reference gene in cDNA by quantitative polymerase chain reaction 5 ⁇ L of premix (containing enzymes and buffers required for PCR), 0-10 ⁇ L of double distilled water (based on total Make up volume to 10 ⁇ L with water), 0 to 2 ⁇ L of dye (for fluorescence compensation and correction of the machine), 1 ⁇ M upstream primer of ALOX15 gene, 1 ⁇ M downstream primer of ALOX15 gene, 1 ⁇ M upstream primer of internal reference gene, 1 ⁇ M Downstream primers for the internal reference gene, 1 ⁇ g positive control, 1 ⁇ g negative control.
  • the manufacturer of the first buffer RWA buffer used was Takara Company, No. 9767; the manufacturer of the second buffer RWB buffer was Takara Company, No. 9767.
  • kits provided in Examples 1 to 6 of the present disclosure can all realize the detection of chronic rhinosinusitis with nasal polyp subtypes.
  • the following are specific test experiments of the kits for detecting chronic rhinosinusitis with nasal polyp subtypes:
  • nasal polyps were obtained under nasal endoscope. Nasal polyps were cut into tissues with a diameter of about 0.5 cm, immersed in RNA stabilization and storage solution (RNAlater), stored at 4 ° C for a short period of time, and then transferred to a storage temperature below -20 ° C for a long time.
  • RNA stabilization and storage solution RNAlater
  • Step 1 Weigh the tissue immersed in RNA stabilization and storage solution (RNAlater). Weigh about 0.01g of tissue into a magnetic beaded centrifuge tube, place it in liquid nitrogen, and grind it on a homogenizer. (3000r, 5min) (or manual grinding). Add 1mL Trizol to the test tube containing the tissue cells to dissolve it, collect it in a centrifuge tube, shake it thoroughly, and leave it at room temperature for 5 minutes; then add 200 ⁇ L of chloroform (trichloromethane) to the RNA extraction reagent group, and shake vigorously to mix. Let stand at room temperature for 5 minutes.
  • Step 2 12,000 rpm, 4 ° C, and centrifuge for 15 minutes.
  • Step 3 Take the supernatant to obtain a volume of about 200 ⁇ L, add it to a centrifuge tube, and add an equal amount (about 200 ⁇ L) of isopropanol to the above RNA extraction reagent group. After mixing, let stand for 10 minutes, 12000 rpm, and centrifuge at 4 ° C for 15 minutes. Discard the supernatant and retain the pellet.
  • Step 4 Add about 200 ⁇ L of 75% ethanol (equivalent to about 150 ⁇ L of anhydrous ethanol and 50 ⁇ L of DNAse and RNase water) of the above-mentioned RNA extraction reagent group (equivalent to isopropanol) to wash the pellet and mix. Centrifuge at 7500 rpm, 4 ° C for 15 minutes. Discard the supernatant and retain the pellet.
  • Step 5 Cap the centrifuge tube tightly and centrifuge at 7500 rpm and 4 ° C for 2 minutes.
  • Step 6 Open the lid, discard the supernatant, and leave it in a fume hood for 15 minutes.
  • Step 7 Add 0.02 mL of RNA hydrolase-free and DNA hydrolase-free (RNase-free and DNase-free) water-soluble precipitates to the above-mentioned RNA extraction reagent group.
  • Step 8 Measure the RNA concentration with a spectrophotometer, and the OD260 / OD280 ratio is between 1.7-2.1.
  • the reverse transcription reaction conditions are as follows:
  • the product was left at 4 ° C.
  • Stage 1 Pre-denaturation: 95 ° C, 30 seconds.
  • Phase 2 PCR reaction: 95 ° C, 15 seconds; 60 ° C, 1 minute annealing extension, for a total of 40 cycles; Phase 2: Melting curve: 60 ° C gradually rises to 95 ° C, the rate is 0.1 ° C / second, Collecting fluorescence;
  • Step 1 Judgment of the quality control of the experiment: The positive control Ct value ⁇ 20 and the negative control Ct value> 38 are regarded as valid experiments, otherwise the experiments are invalid.
  • Step 2 Judgment of typing: The Ct value of the target gene minus the Ct value of the reference gene.
  • the optimal cutoff value of the Ct value of ALOX15 is 1.675. If the Ct value of ALOX15 is greater than 1.675, it is a non-eosinophil. Cellular chronic sinusitis with nasal polyps; if the Ct value of ALOX15 is less than 1.675, it is a typical eosinophilic chronic sinusitis with nasal polyps.
  • Eosinophil type Eosinophil type 44 0.296 Eosinophil type Eosinophil type 45 -1.137 Eosinophil type Eosinophil type 46 3.202 Non-eosinophil type Eosinophil type 47 0.442 Eosinophil type Eosinophil type 48 0.765 Eosinophil type Eosinophil type 49 2.253 Non-eosinophil type Eosinophil type 50 0.769 Eosinophil type Eosinophil type 51 2.422 Non-eosinophil type Eosinophil type 52 0.749 Eosinophil type Eosinophil type 53 -3.834 Eosinophil type Eosinophil type 54 1.930 Non-eosinophil type Eosinophil type 55 0.767 Eosinophil type Eosinophil type 56 0.778 Eosinophil type Eosinophil type 57 0.061 Eosinophil type Eosinophil type 58 4.640
  • Step 1 Add 1mL Trizol to the test tube containing the detached cells, dissolve it, shake it thoroughly, and let it stand at room temperature for 5 minutes, then add 200 ⁇ L of chloroform (trichloromethane), mix with vigorous shaking, and let it stand at room temperature for 5 minutes;
  • chloroform trichloromethane
  • Step 2 12,000 rpm, 4 ° C, and centrifuge for 15 minutes;
  • Step 3 Take the supernatant to obtain a volume of about 200 ⁇ L, add to the centrifuge tube, and add the same amount of isopropyl alcohol (about 200 ⁇ L) as chloroform. After mixing, let stand for 10 minutes, 12000 rpm, and centrifuge at 4 ° C for 15 minutes. Discard the supernatant and keep the pellet;
  • Step 4 Add approximately 200 ⁇ L of 75% ethanol (a mixture of approximately 150 ⁇ L of absolute ethanol and 50 ⁇ L of DNAse and RNAse water) to the RNA extraction reagent group (equivalent to isopropyl alcohol), and mix well. 7500 rpm, 4 ° C, centrifugation for 15 minutes, discard the supernatant and retain the pellet;
  • Step 5 Cap the centrifuge tube tightly at 7500 rpm, 4 ° C, and centrifuge for 2 minutes;
  • Step 6 Open the lid, discard the supernatant, and leave it in a fume hood for 15 minutes;
  • Step 7 Add 0.02 mL of RNA-hydrolase-free and DNA-hydrolase-free (RNase-free and DNase-free) water-soluble precipitates to the above-mentioned RNA extraction reagent group;
  • Step 8 Measure the RNA concentration with a spectrophotometer.
  • the OD260 / OD280 ratio is preferably 1.7 to 2.1.
  • Step 1 Place the genomic DNA adsorption column (genomic DNA Spinner Column) on a 2mL collection tube (Collection Tube);
  • Step 2 Transfer the lysate (cell lysate) containing the detached cells into a genomic DNA adsorption column;
  • Step 3 12,000 rpm, centrifuge for 1 minute
  • Step 4 Discard the genomic DNA adsorption column and retain the filtrate in the 2mL collection tube;
  • Step 5 Add 300 ⁇ L of 70% ethanol to the above step 4 (precipitation may occur at this time), and use a pipette to mix the solution uniformly;
  • Step 6 Immediately transfer all the mixed solution (including the precipitate) into an RNA purification column (containing a 2 mL collection tube);
  • Step 7 12,000 rpm, centrifuge for 1 minute, and discard the filtrate. Place the RNA purification column back into the 2mL collection tube;
  • Step 8 Add 500 ⁇ L of the first buffer (Buffer RWA) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Buffer RWA the first buffer
  • Step 9 Add 600 ⁇ L of the second buffer (Buffer RWB) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate.
  • Buffer RWB buffer RWB
  • Step 10 Place the RNA purification column on a 1.5 mL RNAase-free collection tube (RNase Free Colletion Tube), and add 50 ⁇ L of RNA hydrolysis-free distilled water (RNase Free dH2O) or 0.1% to the center of the RNA purification column membrane. Diethyl pyrocarbonate (DEPC) treated water, and allowed to stand at room temperature for 5 minutes;
  • RNase Free Colletion Tube 1.5 mL RNAase-free collection tube
  • RNase Free dH2O RNA hydrolysis-free distilled water
  • DEPC Diethyl pyrocarbonate
  • Step 11 Centrifuge at 12,000 rpm and elute RNA for 2 minutes with de-RNase and de-DNase water;
  • Step 12 Measure the RNA concentration with a spectrophotometer, and the OD260 / OD280 ratio is 2.0.
  • Step 1 Configure 45 ⁇ L of SYBR Green 1 pre-mixed solution; and ROX: 1.8 ⁇ L, mix and divide into 3 parts, respectively A.11.7 ⁇ L; B.11.7 ⁇ L; C.23.4 ⁇ L, add 1ng / Solution A was obtained from ⁇ L positive control, solution B was added to B with 1ng / ⁇ L negative control, and solution C was added from C with 2ng to obtain solution C (SYBR Green Green 1 premix and ROX are products of Takara Company, article number RR820A);
  • Step 2 Configure 8 groups of parallel holes
  • the first and second parallel wells solution A, specific primers for ALOX15 gene, 3.8 ⁇ L sterilized double distilled water;
  • solution B specific primers for ALOX15 gene, 3.8 ⁇ L sterilized double distilled water
  • Step 3 Seal the plate with clear plastic film, centrifuge, and perform the PCR operation.
  • Step 4 Two-step PCR standard procedure:
  • Stage 1 Pre-denaturation: 95 ° C, 30 seconds.
  • Phase 2 Phase 2: PCR reaction: 95 ° C, 15 seconds; 60 ° C, 1 minute annealing extension, 40 cycles were performed. ;
  • kits provided in Examples 1 to 6 of the present disclosure can all realize the detection of chronic rhinosinusitis with nasal polyp subtypes.
  • Example 5 the effect of the kit for detecting chronic rhinosinusitis with nasal polyp subtypes is performed as follows. Detection experiment:
  • RNA stabilization and storage solution RNAlater
  • Step 1 Weigh the tissue immersed in RNA stabilization and storage solution (RNAlater). Weigh about 0.01g of tissue into a magnetic beaded centrifuge tube, place it in liquid nitrogen, and grind it on a homogenizer. (3000r, 5min) (or manual grinding); add 0.3mL cell lysate, 12,000 rpm, centrifuge for 15 minutes;
  • Step 2 Aspirate the supernatant, add 70% ethanol (70% absolute ethanol and 30% DEPC or RNase and DNase water) equal to the volume of the supernatant, and use a pipette to mix the solution uniformly;
  • Step 3 Transfer all the mixed solution (including the precipitate) to the RNA purification column (including the 2mL collection tube) immediately;
  • Step 4 12,000 rpm, centrifuge for 1 minute, and discard the filtrate. Put the RNA purification back into the 2mL collection tube;
  • Step 5 Add 500 ⁇ L of the first buffer solution (Buffer RWA) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Buffer RWA the first buffer solution
  • Step 6 Add 600 ⁇ L of a second buffer (Buffer RWB) to the RNA purification column, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Buffer RWB a second buffer
  • Step 7 Preparation of DNase I reaction solution: Take 5 ⁇ L of 10 ⁇ DNase I buffer, 4 ⁇ L of recombinant DNase I ((RNase-free, 5U / ⁇ L), 41 ⁇ L of RNase-free Double distilled water into a new 1.5mL tube (no RNase) and mix well;
  • Step 8 Add 50 ⁇ L DNase I reaction solution to the center of the RNA purification column membrane, and leave it at room temperature for 15 minutes;
  • Step 9 Add 350 ⁇ L of a second buffer to the center of the RNA purification column membrane, 12,000 rpm, centrifuge for 30 seconds, and discard the filtrate;
  • Step 10 Repeat step 6;
  • Step 11 Reposition the RNA purification column on a 2mL collection tube, 12,000 rpm, and centrifuge for 2 minutes;
  • Step 12 Place the RNA purification column on a 1.5 mL RNAase-free collection tube (RNase Free Colletion Tube), and add 50 ⁇ L of RNAase-free distilled water (RNase Free HdO) or 0.1% to the center of the RNA purification column membrane. Diethyl pyrocarbonate (DEPC) treated water, and allowed to stand at room temperature for 5 minutes;
  • RNase Free Colletion Tube 1.5 RNAase-free collection tube
  • RNase Free HdO RNAase-free distilled water
  • DEPC Diethyl pyrocarbonate
  • Step 13 Centrifuge at 12,000 rpm, and elute RNA for 2 minutes with RNase and DNase-free water;
  • Step 14 Measure the RNA concentration with a spectrophotometer, and the OD260 / OD280 ratio is 2.0;
  • reaction conditions used a standard three-step PCR amplification procedure:
  • Stage 1 Pre-denaturation: 95 ° C, 2 minutes;
  • Phase 2 Phase 2: PCR reaction: 95 ° C, 1 minute; 55 ° C, 1 minute, 72 ° C for 1 minute, a total of 40 cycles were performed, and finally 72 ° C, 7 minutes annealing extension.
  • the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtypes.
  • the screening uses the ALOX15 gene as a biomarker and applies it to the kit to realize the use of the kit to detect chronic
  • the method of sinusitis with nasal polyp subtypes can quickly, accurately and comprehensively identify patients with nasal polyp subtypes through the kit, in order to carry out targeted treatment based on the inflammatory subtypes of nasal polyps as soon as possible, and effectively guide chronic sinusitis.
  • the determination of drug treatment methods and surgical methods for patients with nasal polyps accurately predict the response to drug treatment, and judge the prognostic effect.
  • a method for detecting the expression of ALOX15 gene in exfoliated nasal cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells:
  • Step 1 Take the genomic DNA adsorption column into a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 300 ⁇ L of cell lysate, and add it to the genomic DNA adsorption column. Take the filtrate and add an equal volume of 70% to the filter. Ethanol, after mixing, added to the RNA purification column, 12000 rpm, centrifugation for 1min, the filtrate was removed, and the RNA purification column was placed in a 2mL collection tube;
  • Step 2 Add 500 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 600 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. Leave at room temperature for 5 minutes, 12000 rpm, centrifuge for 2 minutes, elute the RNA purification column, and use a spectrophotometer to measure the OD260 / OD280 ratio of the RNA solution to 2.0 to obtain RNA;
  • Step 2 Prepare cDNA by reverse transcription, including the following steps: take 2 ⁇ L of the reverse transcription mixture, 0-8 ⁇ L of the deRNA hydrolase distilled water (make up to 8 ⁇ L with water according to the amount of RNA), and the total amount does not exceed 500ng Or the total RNA volume is not more than 8 ⁇ L, and the de-RNA hydrolase distilled water is used to make up to 10 ⁇ L.
  • reverse transcription reaction is performed under the following conditions: at 37 ° C, a reverse transcription reaction is performed for 15 minutes; Under the condition of 85 ° C, the reverse transcriptase inactivation reaction was performed for 5 seconds; the product was left at 4 ° C.
  • Step 3 Real-time quantitative PCR amplification detection, including the following steps:
  • Step 1 Prepare a real-time PCR reaction solution: include 1 ⁇ L of PCR premix, 0-10 ⁇ L of double distilled water (to make up to 10 ⁇ L with water based on the total volume), 0.2 ⁇ L of machine fluorescence compensation and correction agent, 1 ⁇ M of ALOX15 Gene upstream primer, 1 ⁇ M ALOX15 gene downstream primer, 1 ⁇ M internal reference gene upstream primer, 1 ⁇ M internal reference gene downstream primer, 0.01 ⁇ L of the cDNA, 1 ⁇ g positive control, 1 ⁇ g negative control, positive control contains ALOX15 plasmid, the negative control is an empty plasmid (plasmid vector);
  • Step 2 Standard procedure for two-step PCR amplification: The reaction conditions for the standard procedure for two-step PCR amplification include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR reaction : Reaction was performed at 95 ° C for 15 seconds, and at 60 ° C, reaction was performed for 60 seconds, followed by annealing extension, and 40 cycles were performed.
  • Step 4 Calculate the expression of the ALOX15 gene:
  • ⁇ CT method was used to compare the expression of ALOX15 and the reference gene: the average CT value of ALOX15 was 20.9, the average CT value of GAPDH was 18.9, and the ⁇ CT value was 2.0.
  • a method for detecting the expression of ALOX15 gene in exfoliated nasal cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells:
  • Step 1 Take the genomic DNA adsorption column into a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 100 ⁇ L of cell lysate, add it to the genomic DNA adsorption column, centrifuge at 12000 rpm for 60s, and take the filtrate. Add an equal volume of 70% ethanol to the filter, mix it and add it to the RNA purification column, 12000 rpm, centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 300 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 seconds to remove the first filtrate; continue to add 400 ⁇ L of the second buffer to the RNA purification column Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. Leave at room temperature for 5 minutes, 12000 rpm, centrifuge for 2 minutes, elute the RNA purification column, and use a spectrophotometer to measure the OD260 / OD280 ratio of the RNA solution to 2.0 to obtain RNA;
  • Step 2 Reverse transcription to prepare cDNA, including the following steps: take 1 ⁇ L of the reverse transcription mixture, 0 to 10 ⁇ L of the deRNA hydrolase distilled water, and total RNA not exceeding 500 ng or 8 ⁇ L in volume. Make up the RNA hydrolase distilled water to make up to 10 ⁇ L; gently mix the reverse transcription reaction under the following conditions: at 37 ° C for 15 minutes, and at 85 ° C for 5 seconds Reverse transcriptase inactivation reaction; the product was left at 4 ° C.
  • Step 3 Real-time quantitative PCR amplification detection, including the following steps:
  • Step 1 Prepare a real-time quantitative PCR reaction solution: include 25 ⁇ L of PCR premix, 0 to 10 ⁇ L of double distilled water (to make up to 10 ⁇ L with water based on the total volume), and 0 to 2 ⁇ L of dye (for fluorescence compensation of the machine) And correction), 0.01 ⁇ M ALOX15 gene upstream primer, 0.01 ⁇ M ALOX15 gene downstream primer, 0.01 ⁇ M internal reference gene upstream primer, 0.01 ⁇ M internal reference gene downstream primer, 5 ⁇ L cDNA, 1 ⁇ g positive control, 1 ⁇ g negative Control, the positive control is a plasmid containing ALOX15, and the negative control is an empty plasmid (plasmid vector);
  • Step 2 Standard procedure for two-step PCR amplification: The reaction conditions for the standard procedure for two-step PCR amplification include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR reaction : Reaction was performed at 95 ° C for 15 seconds, and at 60 ° C, reaction was performed for 60 seconds, followed by annealing extension, and 40 cycles were performed.
  • Step 4 Calculate the expression of the ALOX15 gene:
  • ⁇ CT method was used to compare the expression difference of ALOX15 and internal reference genes: the average CT value of ALOX15 was 19.5, the average CT value of GAPDH was 18.0, and the ⁇ CT value was 1.5.
  • a method for detecting the expression of ALOX15 gene in exfoliated nasal cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells:
  • Step 1 Take the genomic DNA adsorption column into a 2mL collection tube, dissolve the nasal cavity exfoliated cells in 2000 ⁇ L of cell lysate, add it to the genomic DNA adsorption column, centrifuge at 12000 rpm for 60 seconds, and take the filtrate. Add an equal volume of 70% ethanol to the filter, mix it and add it to the RNA purification column, 12000 rpm, centrifuge for 1min, remove the filtrate, and place the RNA purification column in a 2mL collection tube;
  • Step 2 Add 700 ⁇ L of the first buffer to the RNA purification column obtained in step 1, centrifuge at 12,000 rpm for 30 s to remove the first filtrate; continue to add 800 ⁇ L of the second buffer to the RNA purification column, Centrifuge at 12000 rpm for 30 seconds to remove the second filtrate;
  • Step 3 Place the RNA purification column with the second filtrate removed in step 2 into a 1.5 mL RNA hydrolase-free collection tube. Add 50 ⁇ L of RNA hydrolase-free distilled water or 0.1% diethyl pyrocarbonate-treated water to the RNA purification column. Leave at room temperature for 5 minutes, 12000 rpm, centrifuge for 2 minutes, elute the RNA purification column, and use a spectrophotometer to measure the OD260 / OD280 ratio of the RNA solution to 2.0 to obtain RNA;
  • Step 2 Reverse transcription to prepare cDNA, including the following steps: take 3 ⁇ L of the reverse transcription mixture, 0-8 ⁇ L of RNase and DNAse-free water (make up to 8 ⁇ L with water according to the amount of RNA), and the total amount does not exceed 500ng or total volume of no more than 8 ⁇ L, the deRNA hydrolase distilled water was made up to 10 ⁇ L; the reverse transcription reaction was performed after gentle mixing, the conditions were as follows: at 37 ° C, a reverse transcription reaction was performed for 15 minutes; Under the condition of 85 ° C, the reverse transcriptase inactivation reaction was performed for 5 seconds; the product was left at 4 ° C.
  • Step 3 Real-time quantitative PCR amplification detection, including the following steps:
  • Step 1 Prepare a real-time PCR reaction solution: include 5 ⁇ L of premixed solution (containing enzymes and buffers required for PCR), 0-10 ⁇ L of double-distilled water (make up to 10 ⁇ L with water based on the total volume), and 0 to 2 ⁇ L of Dye (for fluorescence compensation and correction of the machine), 1 ⁇ M upstream primer of ALOX15 gene, 1 ⁇ M downstream primer of ALOX15 gene, 1 ⁇ M upstream reference gene of primer, 1 ⁇ M downstream reference gene of primer, 2 ⁇ L of cDNA, 1 ⁇ g Positive control, 1 ⁇ g negative control;
  • Step 2 Standard procedure for two-step PCR amplification:
  • the reaction conditions for the standard procedure for two-step PCR amplification include the following steps: Stage 1: Pre-denaturation for 30 seconds at 95 ° C; Stage 2 PCR : Reaction was performed at 95 ° C for 15 seconds, and at 60 ° C, reaction was performed for 60 seconds, followed by annealing extension, and 40 cycles were performed.
  • Step 4 Calculate the expression of the ALOX15 gene:
  • ⁇ CT method was used to compare the expression of ALOX15 and internal reference genes: the average CT value of ALOX15 was 20.1, the average CT value of GAPDH was 17.9, and the ⁇ CT value was 2.2.
  • the preferred manufacturer of the first buffer RWA buffer used is Takara Company, article number 9767; the manufacturer of the second buffer RWB buffer is Takara Company, article number 9767.
  • the protection scope of the present application is not limited to the first buffer solution and the second buffer solution described above. Those skilled in the art can choose according to the actual application needs.
  • nasal endoscope was used to press the surface of the nasal polyps with a brush (Copan) for 30 seconds, rotated 3-4 times to brush the surface of the polyp, and the brush was placed in a subsequent place.
  • the lysate is stored at 4 ° C for short-term storage (no more than 24 hours), or transferred to long-term storage below -20 ° C.
  • a method for detecting the expression of ALOX15 gene in exfoliated nasal cells comprising the following steps:
  • Step 1 Extract RNA from exfoliated nasal cells: add 1mL RNA extraction solution to the centrifuge tube containing detached nasal cells, dissolve and shake, and let stand at room temperature for 5min; add 200 ⁇ L of chloroform, mix by shaking, and let stand at room temperature for 5min. Centrifuge at 12000 r / min for 15 min at 4 ° C. Take 200 ⁇ L of the supernatant, add 200 ⁇ L isopropanol, mix and let stand for 10 min. Centrifuge at 4 ° C, 12000 r / min for 15 min. Discard the supernatant and retain the first pellet.
  • Step 2 The steps for preparing cDNA by reverse transcription are the same as in Example 7.
  • Step 3 The detection steps of real-time quantitative PCR amplification are the same as those in Example 7.
  • Step 4 Calculate the expression of the ALOX15 gene:
  • Step 1 Calculate the average ⁇ CT of the healthy control group:
  • subjects 1 to 10 are healthy control groups.
  • Step 2 Calculate the relative expression of the subject:
  • the patient was instructed to flush the nasal cavity with normal saline, and under a nasal endoscope, press the surface of the nasal polyp with a brush (Copan) for 30 seconds, rotate 3-4 times, brush the surface of the polyp, and place the brush in the lysate , Short-term storage at 4 ° C (not more than 24 hours), or transfer to long-term storage below -20 ° C.
  • a brush Copan
  • a method for detecting the expression of ALOX15 gene in exfoliated nasal cells comprising the following steps:
  • Step 1 Extract RNA from the nasal cavity exfoliated cells: Add 20mL RNA extraction solution to the centrifuge tube containing the nasal cavity exfoliated cells, dissolve and shake, and let stand at room temperature for 7min; add 10mL of chloroform, shake and mix, and leave at room temperature for 7min Centrifuge at 5 ° C, 14000r / min for 20min; take 20mL of supernatant, add 20mL of isopropanol, mix well and let stand for 12min, centrifuge at 5 ° C, 14000r / min for 20min, discard the supernatant, and retain the first precipitate; 40 mL of 90% ethanol was added to the first pellet, centrifuged at 14000 r / min for 3 min at 5 ° C, the supernatant was discarded, and the second pellet was retained; the centrifuge tube was capped, and centrifuged at 5 ° C, 14000 r / min for 3 min After removing the supernatant, let it stand for 20 minutes,
  • Step 2 The steps for preparing cDNA by reverse transcription are the same as in Example 7.
  • Step 3 The preparation of the real-time quantitative PCR reaction solution in the real-time quantitative PCR amplification detection step is the same as in Example 7.
  • a standard three-step method for PCR amplification is adopted.
  • the reaction conditions of the standard three-step PCR standard procedure include The following steps: Phase 1: Pre-denaturation at 95 ° C for 2 minutes; Phase 2 PCR reaction: Reaction at 95 ° C for 1 minute, at 55 ° C for 1 minute, at 72 ° C Under the conditions, the reaction was performed for 1 minute, and thus 40 cycles were performed; finally, 72 ° C, 7 minutes of annealing extension.
  • Step 4 Calculate the expression of the ALOX15 gene:
  • the patient was instructed to flush the nasal cavity with normal saline, and under a nasal endoscope, press the surface of the nasal polyp with a brush (Copan) for 30 seconds, rotate 3-4 times, brush the surface of the polyp, and place the brush in the lysis solution , Short-term storage at 4 ° C (not more than 24 hours), or transfer to long-term storage below -20 ° C.
  • a brush Copan
  • a method for detecting the expression of ALOX15 gene in exfoliated nasal cells comprising the following steps:
  • Step 1 Extract RNA from nasal cavity exfoliated cells. Add 0.1mL RNA extraction solution to the centrifuge tube containing nasal exfoliated cells, dissolve and shake, and let stand at room temperature for 7min. Add 0.03mL of chloroform, shake and mix, and leave at room temperature.
  • Step 2 The steps for preparing cDNA by reverse transcription are the same as in Example 7.
  • Step 3 The preparation of the real-time quantitative PCR reaction solution in the real-time quantitative PCR amplification detection step is the same as in Example 7.
  • a standard three-step method for PCR amplification is adopted.
  • the reaction conditions of the standard three-step PCR standard procedure include The following steps: Phase 1: Pre-denaturation at 95 ° C for 2 minutes; Phase 2 PCR reaction: Reaction at 95 ° C for 1 minute, at 55 ° C for 1 minute, at 72 ° C Under the conditions, the reaction was performed for 1 minute, and thus 40 cycles were performed; finally, 72 ° C, 7 minutes of annealing extension.
  • Step 4 Calculate the expression of the ALOX15 gene:
  • the expression of ALOX15 in this patient is 0.51 times (1/2 1.4 ) of GAPDH.
  • the present disclosure provides a kit for detecting chronic sinusitis with nasal polyp subtypes.
  • the proteomics and transcriptomics methods are used to select the ALOX15 gene as a biomarker and apply it to the kit to realize the use of reagents.
  • the kit is used to detect chronic sinusitis with nasal polyp subtypes, so that the final obtained kit includes a specific primer for the ALOX15 gene. Based on the specific primers, the kit of the present disclosure can quickly identify nasal polyp subtypes, and is more accurate than traditional pathological detection methods.
  • the kit can simultaneously perform large-scale, rapid Testing, saving labor costs and medical treatment costs. And the systematic kit has high identification accuracy, which can fully reflect the histopathological characteristics.
  • the kit provided by the present disclosure can detect nasal polyp cells from the surface of the nasal polyp by brushing or sticking, so as to determine the chronic sinusitis of the patient with nasal polyp subtypes, thereby avoiding wounds to the patient.
  • the safety of patient examination is improved, the operation is more convenient, and the labor cost and medical treatment cost are saved.
  • the method for detecting the expression level of ALOX15 gene in nasal exfoliated cells uses the effectively selected ALOX15 gene as a biomarker to provide a method for detecting the expression level of the gene and realize calculation of the expression level of ALOX15 gene in nasal exfoliated cells. It can effectively obtain the expression level of ALOX15 gene.
  • the method provided is simple and fast, high sensitivity, good reproducibility, and is suitable for wide application.
  • the present disclosure provides a method for detecting the expression level of ALOX15 gene in nasal exfoliated cells, wherein the ALOX15 gene can encode a lipoxygenase protein, and the encoded enzyme acts on various polyunsaturated fatty acid substrates to produce various biologically active lipid mediators, For example, eicosanoid, heparin, lipoxin and so on.
  • the arachidonic acid was converted into 12-eicosatetraenoic acid / 12-HPETE and 15-eicosatetraenoic acid / 15-HPETE. It also converts linoleic acid into 13-hydroperoxyoctadecadienoic acid.
  • ALOX15 can also act on (12S) -hydrogen peroxytetraenoic acid / (12S) -HPETE to produce heparin A3.
  • the encoded enzyme and its reaction products can regulate inflammation and immune response.
  • Diseases related to ALOX15 include softening of white matter around the ventricle. It helps clear apoptotic cells during inflammation by oxidizing membrane-bound phosphatidylethanolamine in macrophages, and inhibits autoimmune responses associated with inflammatory monocytes clearing apoptotic cells.
  • the ALOX15 gene has not been disclosed in the prior art, and the use of the gene has not been found.
  • the method for the expression of ALOX15 gene in exfoliated nasal cells can be used to detect the expression of ALOX15 in exfoliated nasal cells, and it can be used to further provide a basis for the gene screening technology for detecting chronic sinusitis subtypes with nasal polyps, It provides a reliable basis for clinical guidance and drug treatment. The feasibility of the kit for detecting chronic sinusitis subtype with nasal polyps in clinical application is guaranteed.
  • Nasal shedding was detected ALOX15 gene expression in cells of the present disclosure provides, according to actual needs or relative quantitation method using ⁇ Ct 2 - ⁇ Ct method, the expression of selected relatively constant reference gene, normalized by the number of reference genes by The difference between the Ct value of the target gene of the sample and the internal reference gene is calculated to calculate the expression amount of the target gene.
  • the method is simple and fast, the detection accuracy is high, the detection cost can be reduced, and the detection time can be saved. The result is easy to interpret and so on. Greatly improved the experimental efficiency.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un kit de détection d'une rhino-sinusite chronique avec un sous-type de polypes nasaux et l'utilisation d'un gène ALOX15 en tant que biomarqueur. L'invention concerne également un procédé de détection de la quantité d'expression du gène ALOX15 dans des cellules larguées dans une cavité nasale ainsi que son utilisation. Le kit comprend des amorces spécifiques du gène ALOX15. Le gène ALOX15, en tant que biomarqueur, peut être transformé en un produit pour détecter une rhino-sinusite chronique avec un sous-type de polypes nasaux. Le procédé de détection de la présente invention comprend les étapes suivantes : extraction d'ARN de cellules larguées dans la cavité nasale, transcription inverse de l'ARN total en ADNc, réalisation d'une amplification par PCR quantitative en temps réel de détection de la fluorescence du gène ALOX15 et d'un gène de référence de l'ADNc respectivement avec les amorces spécifiques du gène ALOX15 et des amorces spécifiques du gène de référence au moyen d'une amplification en chaîne par polymérase quantitative, et calcul de la quantité d'expression du gène ALOX15 sur la base d'un résultat de détection d'un produit d'amplification.
PCT/CN2019/093281 2018-07-03 2019-06-27 Procédé et kit de détection d'une rhino-sinusite chronique avec un sous-type de polypes nasaux et utilisation du gène alox15 en tant que biomarqueur WO2020007227A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810717413.X 2018-07-03
CN201810717413.XA CN108949954A (zh) 2018-07-03 2018-07-03 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及alox15基因作为生物标志物的应用
CN201810720285.4 2018-07-03
CN201810720285.4A CN108913764A (zh) 2018-07-03 2018-07-03 检测鼻腔脱落细胞中alox15基因表达量的方法及应用

Publications (1)

Publication Number Publication Date
WO2020007227A1 true WO2020007227A1 (fr) 2020-01-09

Family

ID=69060061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/093281 WO2020007227A1 (fr) 2018-07-03 2019-06-27 Procédé et kit de détection d'une rhino-sinusite chronique avec un sous-type de polypes nasaux et utilisation du gène alox15 en tant que biomarqueur

Country Status (1)

Country Link
WO (1) WO2020007227A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102232113A (zh) * 2008-03-31 2011-11-02 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
CN105849280A (zh) * 2013-10-23 2016-08-10 豪夫迈·罗氏有限公司 诊断和治疗嗜酸性粒细胞紊乱的方法
CN108913764A (zh) * 2018-07-03 2018-11-30 张罗 检测鼻腔脱落细胞中alox15基因表达量的方法及应用
CN108949954A (zh) * 2018-07-03 2018-12-07 张罗 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及alox15基因作为生物标志物的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102232113A (zh) * 2008-03-31 2011-11-02 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
CN105849280A (zh) * 2013-10-23 2016-08-10 豪夫迈·罗氏有限公司 诊断和治疗嗜酸性粒细胞紊乱的方法
CN108913764A (zh) * 2018-07-03 2018-11-30 张罗 检测鼻腔脱落细胞中alox15基因表达量的方法及应用
CN108949954A (zh) * 2018-07-03 2018-12-07 张罗 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及alox15基因作为生物标志物的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAN BING ET AL.: "Expression and corticosteroid Inhibition of Arachidonate 15-lipoxygenase in chronic rhinosinusitis with Nasal Polyps", JOURNAL OF CAPITAL MEDICAL UNIVERSITY, vol. 38, no. 5, 31 October 2017 (2017-10-31) *

Similar Documents

Publication Publication Date Title
JP5416110B2 (ja) ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法
EP3235910A1 (fr) Procédé d'identification de pathogènes de maladies infectieuses bactériennes à l'aide de nanovésicules dérivées de bactéries
JP2010536372A5 (fr)
JP2014508525A (ja) ヒトゲノムに対応するポリヌクレオチドの初期セットから患者の宿主応答の重症度をインビトロ決定するためのポリヌクレオチドのサブセットを同定するための方法
EP2920321B1 (fr) Dosage d'acide nucléique pour le diagnostic ou la surveillance d'une infection par un pathogène dans un fluide corporel provenant d'un sujet traité par un agent anti-pathogène
US20170283789A1 (en) Methods for collecting cervical-vaginal fluids and isolating exosome and microvesicles for molecular analysis
CN108841949B (zh) 帕金森病早期检测和诊断试剂盒及装置
JP2012080853A (ja) 抗酸菌ｄｎａの抽出精製法
Li et al. Promising novel biomarkers and therapy targets: The application of cell-free seminal nucleotides in male reproduction research
JP7560112B2 (ja) Ｐｖａスポンジを用いるリキッドバイオプシーの調製方法
CN109536502B (zh) 一种适用于妊娠滋养细胞肿瘤患者血浆外泌体miRNA的PCR内参
US20140378334A1 (en) Method for quantifying renal markers by assaying urine
WO2020007227A1 (fr) Procédé et kit de détection d'une rhino-sinusite chronique avec un sous-type de polypes nasaux et utilisation du gène alox15 en tant que biomarqueur
CN108913762A (zh) 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及cst1基因作为生物标志物的应用
CN108707661B (zh) Clc基因的特异性引物在制备用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒的应用
CN116769892A (zh) circRNA生物标志物在抑郁症诊断中的应用
KR102229647B1 (ko) 신장이식 환자의 급성거부반응 진단용 miRNA 바이오 마커 및 이의 용도
CN109266750B (zh) 用于鼻咽癌诊断的生物标志物以及应用
CN112342317A (zh) Ihhnv病毒lamp-crispr等温检测用的核酸序列组合、试剂盒及检测方法
CN112646876A (zh) 用于银屑病诊断的miRNA及其应用
CN108949954A (zh) 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及alox15基因作为生物标志物的应用
WO2020007228A1 (fr) Utilisation de la cystatine sn dans la détection d'une rhinosinusite chronique avec un sous-type de polypes nasaux et prédiction de la sensibilité d'un patient à un glucocorticoïde
WO2020007230A1 (fr) Procédé et kit de détection de sinusite chronique avec un sous-type de polypes nasaux et l'application d'un gène ou d'une protéine clc en tant que biomarqueur
CN115992220B (zh) 一种类风湿关节炎的分子标记及应用
TW202340478A (zh) 用於鼻咽癌診斷的試劑和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19830420

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19830420

Country of ref document: EP

Kind code of ref document: A1